Clinical Efficacy and Safety Comparative Study Between CMAB807 Injection and Prolia® .

NCT04591275 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

278

Enrollment

INDUSTRY

Sponsor class

Conditions

Postmenopausal Osteoporosis

Interventions

DRUG: CMAB807 Injection
DRUG: Prolia®

Sponsor

Shanghai Biomabs Pharmaceutical Co., Ltd.